Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer (2022)
Attributed to:
Using MHC class I peptides to modulate NK cell activity, as a basis for immunotherapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/vaccines10121993
PubMed Identifier: 36560403
Publication URI: http://europepmc.org/abstract/MED/36560403
Type: Journal Article/Review
Parent Publication: Vaccines
Issue: 12
ISSN: 2076-393X